BEDFORD, Mass.--(BUSINESS WIRE)--Jul. 31, 2017--
Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical company
focused on the development, manufacturing and commercialization of
innovative therapies for diseases and conditions of the eye, today
announced that it will report second quarter 2017 financial results on
Tuesday, August 8, 2017. Following distribution of the earnings release
via wire services, the Ocular Therapeutix management team will host a
live conference call and webcast at 5:00 p.m. Eastern Time to review the
Company’s financial results and provide a general business update.
The live webcast can be accessed by visiting the Investors section of
the Company’s website at investors.ocutx.com. Please connect at least 15
minutes prior to the live webcast to ensure adequate time for any
software download that may be needed to access the webcast.
Alternatively, please call 844-464-3934 (U.S.) or 765-507-2620
(International) to listen to the live conference call. The conference ID
number for the live call will be 59980638. An archive of the webcast
will be available until August 22, 2017 on the Company’s website.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the
development, manufacturing and commercialization of innovative therapies
for diseases and conditions of the eye using its proprietary hydrogel
platform technology. Ocular Therapeutix’s lead product candidate,
DEXTENZA™ (dexamethasone insert) 0.4 mg for intracanalicular use has
completed Phase 3 clinical development for the treatment of ocular pain
and inflammation following ophthalmic surgery. OTX-TP (travoprost
insert) is in Phase 3 clinical development for glaucoma and ocular
hypertension. Ocular Therapeutix is also evaluating injectable drug
delivery depots for back-of-the-eye diseases. Ocular Therapeutix's first
product, ReSure® Sealant, is FDA-approved to seal corneal incisions
following cataract surgery.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170731005689/en/
Source: Ocular Therapeutix, Inc.
Steve Klass, 212-213-0006
Interim Chief Financial Officer
Vice President of Marketing &